Microbot Medical (NASDAQ:MBOT) was upgraded by analysts at Roth Capital to a "strong-buy" rating. They now have a $5.50 price target on the stock.
Microbot Medical (NASDAQ:MBOT) is now covered by analysts at Roth Capital. They set a "buy" rating on the stock.
Microbot Medical (NASDAQ:MBOT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System
Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.